Evaluation of Drug—Drug Interactions in EGFR-Mutated Non-Small-Cell Lung Cancer Patients during Treatment with Tyrosine-Kinase Inhibitors

Evaluation of Drug—Drug Interactions in EGFR-Mutated Non-Small-Cell Lung Cancer Patients during Treatment with Tyrosine-Kinase Inhibitors

(1) Background. The onset of a drug–drug interaction (DDI) may affect treatment efficacy and toxicity of advanced non-small-cell lung cancer (aNSCLC) patients during epidermal growth factor receptor (EGFR) tyrosine-kinase inhibitor (TKI) use. Here we present the use of Drug-PIN<sup>®</sup&g...

Full description

Bibliographic Details
Main Authors: Mario Occhipinti, Marta Brambilla, Giulia Galli, Sara Manglaviti, Maristella Giammaruco, Arsela Prelaj, Roberto Ferrara, Alessandro De Toma, Claudia Proto, Teresa Beninato, Emma Zattarin, Giuseppe Lo Russo, Alain Jonathan Gelibter, Maurizio Simmaco, Robert Preissner, Marina Chiara Garassino, Filippo De Braud, Paolo Marchetti
Format: Article
Language:English
Published: MDPI AG 2021-05-01
Series:Journal of Personalized Medicine
Subjects:
drug–drug interactions (DDI)
EGFR
tyrosine-kinase inhibitors (EGFR-TKIs)
non-small-cell lung cancer (NSCLC)
Drug-PIN<sup>®</sup>
Online Access:https://www.mdpi.com/2075-4426/11/5/424

Internet

https://www.mdpi.com/2075-4426/11/5/424

Similar Items